Purple Biotech Ltd Market Cap ($4.84 Million)
Market Cap & Net Worth: Purple Biotech Ltd (PPBT)
Purple Biotech Ltd market cap. Purple Biotech Ltd (TA:PPBT) has a market capitalization of $4.84 Million (ILA1.81 Billion) as of November 4, 2026. Listed on the TA stock exchange, this Israel-based company holds position #28584 globally and #414 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Purple Biotech Ltd's stock price ILA1.00 by its total outstanding shares 1806089801 (1.81 Billion). Also see cash efficiency ratio of Purple Biotech Ltd for how efficiently the company converts equity into cash flow.
Purple Biotech Ltd Market Cap History (2015–2026)
Purple Biotech Ltd market cap history from 2015 to 2026. Data shows change from $292.46 Million to $4.84 Million (-37.99% CAGR). Check Purple Biotech Ltd share price for real-time trading data and today's change.
Purple Biotech Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Purple Biotech Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Purple Biotech Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
606.71x
Purple Biotech Ltd's market cap is 606.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.25 Billion | $1.00 Million | -$5.20 Million | 1249.25x | N/A |
| 2019 | $1.23 Billion | $1.00 Million | -$5.85 Million | 1234.24x | N/A |
| 2020 | $606.71 Million | $1.00 Million | -$28.00 Million | 606.71x | N/A |
Competitor Companies of PPBT by Market Capitalization
Companies near Purple Biotech Ltd in the global market cap rankings as of November 4, 2026. Also see Purple Biotech Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Purple Biotech Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Purple Biotech Ltd (2015–2026)
Market capitalization of Purple Biotech Ltd from 2015 to today. Between 2015 and today, Purple Biotech Ltd's market cap moved from $292.46 Million to $ 4.84 Million, with a yearly change of -37.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA4.84 Million | -23.08% |
| 2025 | ILA6.29 Million | -83.33% |
| 2024 | ILA37.77 Million | -75.55% |
| 2023 | ILA154.46 Million | -37.70% |
| 2022 | ILA247.91 Million | -57.15% |
| 2021 | ILA578.63 Million | -4.63% |
| 2020 | ILA606.71 Million | -50.84% |
| 2019 | ILA1.23 Billion | -1.20% |
| 2018 | ILA1.25 Billion | -67.09% |
| 2017 | ILA3.80 Billion | -34.12% |
| 2016 | ILA5.76 Billion | +1870.20% |
| 2015 | ILA292.46 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Purple Biotech Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.84 Million USD |
| MoneyControl | $4.84 Million USD |
| MarketWatch | $4.84 Million USD |
| marketcap.company | $4.84 Million USD |
| Reuters | $4.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more